Search results for "urologic and male genital diseases"

showing 10 items of 459 documents

Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy.

2017

Abstract Background Oxidative stress is evident from an early stage in chronic kidney disease (CKD). Therefore, we investigated redox biomarkers in polycystic kidney disease (ADPKD) and IgA nephropathy (IGAN). Methods This is a case-control study with three groups: ADPKD (n = 54), IGAN (n = 58) and healthy controls (n = 86). The major plasma aminothiols with their redox species were examined: homocysteine (Hcy), cysteinglycine (CG), cysteine (Cys) and glutathione (GSH). The redox ratio was the ratio of reduced free and oxidized aminothiols in plasma. We investigated malonedialdehyde (MDA) and advanced oxidation protein products (AOPP), and ten single nucleotide polymorphisms of antioxidant …

0301 basic medicineAdultMaleRiskmedicine.medical_specialtyHomocysteineClinical Biochemistry030232 urology & nephrologyAutosomal dominant polycystic kidney diseaseurologic and male genital diseasesmedicine.disease_causePolymorphism Single NucleotideNephropathy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinePolycystic kidney diseaseMedicineHumansHomocysteineGenetic Association StudiesProteinuriabusiness.industrySuperoxide DismutaseGlomerulonephritis IGAGeneral MedicineDipeptidesMiddle Agedmedicine.diseasePolycystic Kidney Autosomal DominantPrognosisOxidative Stress030104 developmental biologyEndocrinologychemistryAdvanced Oxidation Protein ProductsCase-Control StudiesDisease ProgressionFemaleGene polymorphismLipid Peroxidationmedicine.symptombusinessOxidoreductasesOxidation-ReductionOxidative stressBiomarkersKidney diseaseClinical biochemistry
researchProduct

β(3)‐Adrenoceptors in the normal and diseased urinary bladder—What are the open questions?

2019

β(3)‐Adrenoceptor agonists are used in the treatment of overactive bladder syndrome. Although the relaxant response to adrenergic stimulation in human detrusor smooth muscle cells is mediated mainly via β(3)‐adrenoceptors, the plasma concentrations of the therapeutic dose of mirabegron, the only clinically approved β(3)‐adrenoceptor agonist, are considerably lower than the EC(50) for causing direct relaxation of human detrusor, suggesting a mechanism of action other than direct relaxation of detrusor smooth muscle. However, the site and mechanism of action of β(3)‐adrenoceptor agonists in the bladder have not been firmly established. Postulated mechanisms include prejunctional suppression o…

0301 basic medicineAgonistmedicine.medical_specialtyAdrenergic receptormedicine.drug_classUrinary BladderAdrenergic beta-3 Receptor Agonistsurologic and male genital diseasesThemed Section: Review Articles03 medical and health sciences0302 clinical medicineTherapeutic indexDesensitization (telecommunications)Internal medicineMedicineAnimalsHumansPharmacologyUrinary bladderRelaxation (psychology)business.industry030104 developmental biologymedicine.anatomical_structureEndocrinologyMechanism of actionReceptors Adrenergic beta-3medicine.symptombusinessMirabegron030217 neurology & neurosurgerymedicine.drug
researchProduct

Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

2016

AbstractWe have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas those of other ARBs have been included systematically but without intention of completeness. ARBs as a class lower blood pressure in established hypertension and prevent hypertension development in all applicable animal models except those with a markedly suppressed renin–angiotensin system; blood pressure lowering even persists for a considerable time after d…

0301 basic medicineBlood Pressure030204 cardiovascular system & hematologyKidneyurologic and male genital diseasesBenzoatesAnimals Genetically ModifiedRenin-Angiotensin SystemGene Knockout Techniques0302 clinical medicineAzilsartanPharmacology (medical)TelmisartanOxadiazolesKidneybiologyStrokemedicine.anatomical_structureCardiovascular DiseasesHypertensionDrug Therapy Combinationmedicine.drugmedicine.medical_specialty03 medical and health sciencesMetabolic DiseasesCulture TechniquesInternal medicineRenin–angiotensin systemmedicineAnimalsHumansAntihypertensive AgentsPharmacologyAngiotensin II receptor type 1business.industryAngiotensin-converting enzymeAtherosclerosisLipid Metabolismmedicine.diseaseDisease Models AnimalGlucose030104 developmental biologyBlood pressureEndocrinologyPathophysiology of hypertensionbiology.proteinBenzimidazolesEndothelium VascularTelmisartanbusinessAngiotensin II Type 1 Receptor BlockersPharmacology & Therapeutics
researchProduct

2021

The prognosis for advanced prostate carcinoma (PCa) remains poor due to development of therapy resistance, and new treatment options are needed. Shikonin (SHI) from Traditional Chinese Medicine has induced antitumor effects in diverse tumor entities, but data related to PCa are scarce. Therefore, the parental (=sensitive) and docetaxel (DX)-resistant PCa cell lines, PC3, DU145, LNCaP, and 22Rv1 were exposed to SHI [0.1–1.5 μM], and tumor cell growth, proliferation, cell cycling, cell death (apoptosis, necrosis, and necroptosis), and metabolic activity were evaluated. Correspondingly, the expression of regulating proteins was assessed. Exposure to SHI time- and dose-dependently inhibited tum…

0301 basic medicineCancer ResearchProgrammed cell deathCell cycle checkpointChemistryNecroptosisfungiCellCell cycleurologic and male genital diseases03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinemedicine.anatomical_structureOncologyDU145030220 oncology & carcinogenesisLNCaPCancer researchmedicineGrowth inhibitionCancers
researchProduct

Exosomes in semen: opportunities as a new tool in prostate cancer diagnosis

2017

Abstract: Prostate cancer (PCa) is the most common cancer in men. Nowadays, it is diagnosed through the test of serum prostate-specific antigen (PSA) and rectal examination; however, there is still debate about the PSA-based diagnosis. Seminal fluid (SF), contains a high concentration of subcellular lipid-bound microparticles, traditionally termed "prostasomes", that are extracellular vesicles (EVs) released into the extracellular space by prostate gland's epithelial cells. These vesicles, first described in 1982 promote motility of sperm cells, regulation of sperm cell capacitation, acrosome reaction and immune suppression within the female reproductive tract. It was demonstrated that pros…

0301 basic medicineCancer ResearchSexual transmissionAcrosome reactionSemenimmunomodulationurologic and male genital diseasesMetastasisAndrology03 medical and health sciencesProstate cancermedicineexosomeRadiology Nuclear Medicine and imagingProstate cancer (PCa)Prostate cancer (PCa); exosomes; seminal liquid; immunomodulationbusiness.industrymedicine.diseaseSpermMicrovesicles030104 developmental biologyOncologyProstasomesHuman medicineseminal liquidbusinessTranslational Cancer Research
researchProduct

Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis

2020

Although innovative therapeutic concepts have led to better treatment of advanced renal cell carcinoma (RCC), efficacy is still limited due to the tumor developing resistance to applied drugs. Artesunate (ART) has demonstrated anti-tumor effects in different tumor entities. This study was designed to investigate the impact of ART (1&ndash

0301 basic medicineCancer ResearchTraditional Chinese Medicine (TCM) growth inhibition ferroptosis reactive oxygen species (ROS)Cell cycle checkpointBiologyurologic and male genital diseasesreactive oxygen species (ROS)lcsh:RC254-282Articlegrowth inhibition03 medical and health scienceschemistry.chemical_compound0302 clinical medicinerenal cell carcinoma (RCC)medicineClonogenic assayCytotoxicityartesunate (ART)SunitinibTraditional Chinese Medicine (TCM)Cell cyclelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensferroptosissunitib resistance030104 developmental biologyOncologychemistryCell cultureApoptosis030220 oncology & carcinogenesisCancer researchGrowth inhibitionmedicine.drugCancers
researchProduct

A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development.

2017

Summary Concomitant hepatocyte apoptosis and regeneration is a hallmark of chronic liver diseases (CLDs) predisposing to hepatocellular carcinoma (HCC). Here, we mechanistically link caspase-8-dependent apoptosis to HCC development via proliferation- and replication-associated DNA damage. Proliferation-associated replication stress, DNA damage, and genetic instability are detectable in CLDs before any neoplastic changes occur. Accumulated levels of hepatocyte apoptosis determine and predict subsequent hepatocarcinogenesis. Proliferation-associated DNA damage is sensed by a complex comprising caspase-8, FADD, c-FLIP, and a kinase-dependent function of RIPK1. This platform requires a non-apop…

0301 basic medicineGenome instabilityMaleliver; Hepatocellular carcinoma; DNA damage response; replication stress; apoptosisCancer ResearchDNA RepairCarcinogenesisFas-Associated Death Domain ProteinApoptosisurologic and male genital diseasesDNA damage responseDna Damage Response ; Apoptosis ; Hepatocellular Carcinoma ; Liver ; Replication StressHistonesMice0302 clinical medicineRisk FactorsFADDPhosphorylationCellular SenescenceCaspase 8biologyLiver Neoplasmshepatocellular carcinomaLiver regeneration3. Good healthHistoneOncologyReceptors Tumor Necrosis Factor Type I030220 oncology & carcinogenesisReceptor-Interacting Protein Serine-Threonine KinasesFemalebiological phenomena cell phenomena and immunityCell agingCarcinoma HepatocellularDNA damageDNA repairreplication stressCaspase 8liverArticleGenomic Instability03 medical and health sciencesAnimalsHepatectomyHumansCrosses GeneticCell ProliferationJNK Mitogen-Activated Protein KinasesCell BiologyLiver Regeneration030104 developmental biologyImmunologyChronic Diseasebiology.proteinCancer researchHepatocytesMyeloid Cell Leukemia Sequence 1 ProteinDNA Damage
researchProduct

Clinical and hormonal characteristics in heterozygote carriers of congenital adrenal hyperplasia

2020

Abstract Non-classical congenital adrenal hyperplasia (NC-CAH) includes a group of genetic disorders due to a broad class of CYP21A2 variants identifying a disease-causing ‘C’ genotype. The heterozygous carriers of CYP21 mutations are at increased risk of developing clinically evident hyperandrogenism, even though clinical and laboratory characteristics are still underestimated. With the aim of obtaining a more accurate delineation of the phenotype of heterozygous carrier of CAH, we analyzed clinical, biochemical and molecular characteristics in a cohort of Sicilian subjects. Fifty-seven females with biallelic and monoallelic CYP21A2 variants classifying NC-CAH (24) and heterozygous carrier…

0301 basic medicineHirsutismHydrocortisoneendocrine system diseasesEndocrinology Diabetes and MetabolismClinical BiochemistryPhysiologyOverweighturologic and male genital diseasesBiochemistrySettore MED/13 - Endocrinologia0302 clinical medicineEndocrinologySettore BIO/10 - BiochimicaGenotypeMedicineChildhirsutismPolycystic ovaryfemale genital diseases and pregnancy complications030220 oncology & carcinogenesisCohortMolecular MedicineFemalemedicine.symptomAdultHeterozygotecongenital hereditary and neonatal diseases and abnormalitiesAdolescentYoung Adult03 medical and health sciencesHumansCongenital adrenal hyperplasiaMolecular BiologyHeterozygous carrierAdrenal Hyperplasia Congenitalbusiness.industryHyperandrogenismCongenital adrenal hyperplasianutritional and metabolic diseasesHeterozygote advantageCell BiologyOverweightmedicine.diseaseOligomenorrhea17OHProgesterone deficiency030104 developmental biologyMutationSteroid 21-HydroxylaseHyperandrogenismbusinessThe Journal of Steroid Biochemistry and Molecular Biology
researchProduct

What happens in hospitals does not stay in hospitals: antibiotic-resistant bacteria in hospital wastewater systems.

2016

Hospitals are hotspots for antimicrobial-resistant bacteria (ARB) and play a major role in both their emergence and spread. Large numbers of these ARB will be ejected from hospitals via wastewater systems. In this review, we present quantitative and qualitative data of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, vancomycin-resistant enterococci and Pseudomonas aeruginosa in hospital wastewaters compared to community wastewaters. We also discuss the fate of these ARB in wastewater treatment plants and in the downstream environment. Published studies have shown that hospital effluents contain ARB, the burden of these bacteria being dependent on their local prevalence. The…

0301 basic medicineMicrobiology (medical)030106 microbiologyWastewater010501 environmental sciencesurologic and male genital diseasesmedicine.disease_cause01 natural sciencesbeta-LactamasesVancomycin-Resistant EnterococciWater Purification03 medical and health sciencesAntibiotic resistance[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance BacterialEscherichia colimedicineHumansVancomycin-resistant EnterococcusSelection GeneticEffluentComputingMilieux_MISCELLANEOUS0105 earth and related environmental sciencesPseudomonas aeruginosabusiness.industryGeneral MedicineAntimicrobialHospitals6. Clean waterAnti-Bacterial Agents3. Good healthBiotechnologyMultiple drug resistanceInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyWastewater13. Climate actionPseudomonas aeruginosaSewage treatmentbusiness
researchProduct

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association f…

2018

Abstract Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict …

0301 basic medicineNephrologyDirect-acting antiviral agentmedicine.medical_treatment030232 urology & nephrologyDiseaseHepacivirusurologic and male genital diseasesSeverity of Illness IndexLiver disease0302 clinical medicineRisk FactorsChronic kidney diseasePrevalenceRenal Insufficiency030212 general & internal medicineChronicCooperative BehaviorChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Antiviral Agents; Cooperative Behavior; Expert Testimony; Hepacivirus; Hepatitis C; Humans; Infectious Disease Medicine; Internal Medicine; Italy; Kidney Transplantation; Nephrology; Renal Insufficiency Chronic; Risk Factors; Severity of Illness Index; Societies; Disease ManagementSocieties MedicalKidney transplantationInfectious Disease Medicineeducation.field_of_studyEvidence-Based MedicineGastroenterologyDisease ManagementHepatitis CGeneral MedicineHepatitis CHCV in renal transplantationHCV infectionInfectious DiseasesTreatment OutcomeChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Hepatology; GastroenterologyItalyNephrologyEmergency Medicine030211 gastroenterology & hepatologyHemodialysisHumanMicrobiology (medical)medicine.medical_specialtyConsensus030106 microbiologyPopulationConsensuAntiviral AgentsRisk Assessment03 medical and health sciencesRenal DialysisInternal medicineChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infectionInternal MedicinemedicineHumansRenal Insufficiency ChroniceducationExpert TestimonyAntiviral AgentHepaciviruHepatologybusiness.industryRisk FactorHepatitis C Chronicmedicine.diseaseKidney TransplantationTransplantationDirect-acting antiviral agentsSocietiesbusinessChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Hepacivirus; Hepatitis C; Humans; Italy; Renal Insufficiency ChronicChronic kidney disease Direct-acting antiviral agents HCV in renal transplantation HCV infection NephrologyKidney disease
researchProduct